Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND (SOHO 2026) - Sep 1, 2026 - Abstract #IBCL-740; Location: LEVEL 3, HALL B3; P3 | "These findings show that epcoritamab+R2 is associated with significantly higher ORR and CR and improved PFS and TTNT vs tafasitamab +R2 positioning epcoritamab+R2 as the new chemotherapy-free standard of care in R/R FL. CD: cluster of differentiation. This abstract has been accepted for presentation at the Annual Congress of the European Hematology Association, June 11–14, 2026, Stockholm, Sweden."
Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology
|
|
Kim M Linton MD 1; Moshe Yair Levy MD 2; Dai Maruyama MD PhD 3; Abel Costa MD 4; Shane Gangatharan MBBS 5; Habte Yimer MD 2; Abualbishr Alshreef MPH,MSc PhD 6; Wenying Quan MS 7; Viktor Chirikov PhD 7; Gauri Sunkersett DO 6; JP Mei PharmD 6; Anthony Wang PhD,MPH 6; Savreet Bains Chawla MS 8; Laura Liao MS 8; Felipe Marques Goncalves MD,MBA 8; Zhijie Ding PhD,MS,MBA 8; Marcel Nijland MD 9
|